Xiao Le
Chief Investment Officer bij Wuxi Apptec, Inc.
Profiel
Xiao Le is currently the Director of Corporate Development & Investment at Wuxi Apptec, Inc. and Vice President at 6 Dimensions Capital.
Previously, Mr. Le worked as a Director at Ambrx, Inc., an Independent Director at Ambrx Biopharma Cayman, Inc., and a Vice President at Frontline Bioventures.
Additionally, Mr. Le served as a Non-Executive Director at CANbridge Pharmaceuticals Inc. from 2020 to 2022.
Mr. Le received an undergraduate degree from The Johns Hopkins University and a graduate degree from MIT Sloan School of Management.
Actieve functies van Xiao Le
| Bedrijven | Functie | Begin |
|---|---|---|
6 Dimensions Capital
 6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Private Equity Investor | 18-05-2017 |
Wuxi Apptec, Inc.
 Wuxi Apptec, Inc. Data Processing ServicesTechnology Services Wuxi Apptec, Inc. provides pharmaceutical and biotechnology services. Its services include discovery, lab testing division, small molecule pharmaceutical development and manufacturing international discovery service unit, WuXi biologics, chemistry, bioanalytical, clinical & regulatory, genome center, biological reagents and WuXi venture fund. The company was founded by Ge Li in December 2000 and is headquartered in St. Paul, MN. | Chief Investment Officer | 01-01-2019 |
Eerdere bekende functies van Xiao Le
| Bedrijven | Functie | Einde |
|---|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Director/Board Member | 05-07-2022 |
| Frontline Bioventures | President | 18-05-2017 |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Director/Board Member | - |
| AMBRX INC | Director/Board Member | - |
Opleiding van Xiao Le
| The Johns Hopkins University | Undergraduate Degree |
| MIT Sloan School of Management | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
| Frontline Bioventures | Finance |
6 Dimensions Capital
6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Finance |
Wuxi Apptec, Inc.
Wuxi Apptec, Inc. Data Processing ServicesTechnology Services Wuxi Apptec, Inc. provides pharmaceutical and biotechnology services. Its services include discovery, lab testing division, small molecule pharmaceutical development and manufacturing international discovery service unit, WuXi biologics, chemistry, bioanalytical, clinical & regulatory, genome center, biological reagents and WuXi venture fund. The company was founded by Ge Li in December 2000 and is headquartered in St. Paul, MN. | Technology Services |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
